KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Dec 2024 value amounting to $85.4 million.

  • CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) rose 6.79% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.0 million, marking a year-over-year increase of 6.79%. This contributed to the annual value of $85.4 million for FY2024, which is 7.45% up from last year.
  • As of FY2024, CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) stood at $85.4 million, which was up 7.45% from $79.4 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) ranged from a high of $85.4 million in FY2024 and a low of $70.7 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $79.4 million (2023), whereas its average is $81.0 million.
  • Data for CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) shows a peak YoY grew of 16.12% (in 2020) over the last 5 years.
  • CRISPR Therapeutics AG's Shares Outstanding (Weighted Average) (Yearly) stood at $70.7 million in 2020, then climbed by 8.31% to $76.5 million in 2021, then climbed by 2.31% to $78.3 million in 2022, then rose by 1.45% to $79.4 million in 2023, then climbed by 7.45% to $85.4 million in 2024.